Potential Effects of Nonsteroidal Anti-Inflammatory Drugs in the Prevention and Treatment of Type 2 Diabetes Mellitus

2016 ◽  
Vol 30 (5) ◽  
pp. 549-556 ◽  
Author(s):  
Pamela Natalia Bellucci ◽  
María Florencia González Bagnes ◽  
Guillermo Di Girolamo ◽  
Claudio Daniel González
Keyword(s):  
Diabetes Mellitus ◽  
Glucose Production ◽  
Endogenous Glucose Production ◽  
Metabolic Effects ◽  
Analgesic Effects ◽  
Peripheral Insulin Resistance ◽  
Patients With Diabetes ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of heterogeneous drugs largely known for their anti-inflammatory, antipyretic, and analgesic effects, which are met by means of the inhibition of the cyclooxygenase (COX) enzymes. Even when their use in patients with diabetes mellitus is limited due to relevant adverse events, some pharmacological and metabolic effects of NSAIDs have been further studied to be potentially beneficial in the prevention and/or treatment of diabetic subjects. Effects on endogenous glucose production, peripheral insulin resistance, pancreatic islet, and systemic inflammation and the insulin clearance have been reported. In this article, we overview the scientific literature of the last 5 years regarding the potential effects of NSAID treatment on diabetes prevention/treatment. The selected papers showed information in both humans and animal models. Furthermore, we included papers that suggest new areas for further investigation, and we discussed our own suggestions on this matter.

Metabolic Effects of Temocapril in Hypertensive Patients with Diabetes Mellitus Type 2

1999 ◽  
Vol 33 (4) ◽  
pp. 527-533 ◽  
Author(s):  
M. Lerch ◽  
P. Weidmann ◽  
M. P. Ho ◽  
P. Gerber ◽  
P. Eckenberger ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Diabetes Mellitus Type 2 ◽  
Diabetes Mellitus Type ◽  
Metabolic Effects ◽  
Hypertensive Patients ◽  
Patients With Diabetes

Impaired suppression of endogenous glucose production in lean Japanese patients with type 2 diabetes mellitus

2011 ◽  
Vol 93 (1) ◽  
pp. e1-e2 ◽  
Author(s):  
Mitsuyoshi Takahara ◽  
Hideaki Kaneto ◽  
Naoto Katakami ◽  
Taka-aki Matsuoka ◽  
Munehide Matsuhisa ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glucose Production ◽  
Japanese Patients ◽  
Endogenous Glucose Production ◽  
Endogenous Glucose

scholarly journals Role Iron in Diabetes mellitus type 2 of the patients in province Diwaniya

2019 ◽  
Vol 13 (1) ◽  
pp. 63-65
Author(s):  
Hussein Mahdi kreem AL-Mohammad
Keyword(s):  
Diabetes Mellitus ◽  
Diabetes Mellitus Type 2 ◽  
Hepatic Glucose Production ◽  
Glucose Production ◽  
Cross Sectional Study ◽  
Diabetes Mellitus Type ◽  
Cross Sectional ◽  
Peripheral Insulin Resistance ◽  
Relative Deficiency

Background: Diabetes mellitus is a common health problem of the world. Iron may be a part of the cause of the disease and its Complications Objectives: This study was designed to determine the relationship between the levels of iron indices  and diabetes mellitus type 2. Type 2 Type of the study: Cross –sectional study. Methods: diabetes mellitus is clinical condition characterized by hyperglycemia due to the absolute or relative deficiency of insulin. It is also followed by pathological abnormalities like impaired insulin secretion, peripheral insulin resistance, and excessive hepatic glucose production. Although type 2 diabetes mellitus is a multiple etiological disease, emerging scientific evidences show there is somewhat related to the disease with iron metabolism  Results: The study includes thirteen (15 female and 15 male)  patient  with  Diabetes mellitus and (15 male and 15 female ) as the control. In the present study, significantly increased (p < 0.05)   At ferretin , iron,  transferitin, transferin saturated  and significant decrease (p < 0.05) EIBS, TIBC  . Conclusions: These results suggest that the role negative of increase iron in development Diabetes mellitus by a number of  mechanisms.  .

Indomethacin Does Not Affect Endogenous Glucose Production in Type 2 Diabetes Mellitus

2001 ◽  
Vol 33 (11) ◽  
pp. 659-663 ◽  
Author(s):  
A. M. Pereira Arias ◽  
P. H. Bisschop ◽  
M. T. Ackermans ◽  
E. Endert ◽  
J. A. Romijn ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glucose Production ◽  
Endogenous Glucose Production ◽  
Endogenous Glucose

scholarly journals Prescribing of Non-Steroidal Anti-Inflammatory Drugs to Patients with Diabetes Mellitus in Portugal

2019 ◽  
Vol 32 (2) ◽  
pp. 119 ◽  
Author(s):  
Miguel Bigotte Vieira ◽  
João Sérgio Neves ◽  
Rute Baeta Baptista ◽  
Lia Leitão ◽  
Catarina Viegas Dias ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Patients With Diabetes ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Introduction: Portugal presents the highest incidence of stage 5 chronic kidney disease in Europe. It is speculated that a high consumption of non-steroidal anti-inflammatory drugs (NSAIDS) may contribute to this high incidence. Our aim was to characterize the prescription of non-steroidal anti-inflammatory drugs to patients with diabetes mellitus in Portugal.Material and Methods: We analyzed the national prescription database in triennium 2015 - 2017. In patients with diabetes mellitus, we evaluated the prescription of non-steroidal anti-inflammatory drugs according to age, gender and region of the patient and specialty of the prescribing physician. We evaluated the prescription of non-steroidal anti-inflammatory drugs in all patients with diabetes mellitus, in patients with presumed renal impairment, and in those with concomitant prescription of angiotensin converting enzyme inhibitors or angiotensin receptor antagonists.Results: We analyzed 23 320 620 prescriptions, corresponding to 610 157 adults, including 104 306 patients with diabetes mellitus. The most prescribed non-steroidal anti-inflammatory drugs were ibuprofen (20.1%), metamizole (14.7%), and diclofenac (11.4%). The prescription of non-steroidal anti-inflammatory drugs was higher in females, in patients aged 51 - 70 years and in the Alentejo region. Non-steroidal anti-inflammatory drugs were prescribed to 70.6% of patients with diabetes mellitus, from which 10.6% were prescribed ≥ 10 packages during the three years. Among patients with diabetes mellitus on angiotensin converting enzyme inhibitors/angiotensin receptor antagonists and with presumed reduction in kidney function, 69.3% were prescribed non-steroidal anti-inflammatory drugs and 11.5% were prescribed ≥ 10 packages during the three years.Discussion: The level of prescribing of non-steroidal anti-inflammatory drugs to patients with diabetes mellitus is high. The concern of reducing non-steroidal anti-inflammatory drugs prescription to patients already on angiotensin converting enzyme inhibitors/angiotensin receptor antagonists and/or decreased renal function does not seem to exist.Conclusion: In Portugal, the level of prescribing of non-steroidal anti-inflammatory drugs to patients with diabetes mellitus should be reduced, particularly in the subgroups identified with higher prescription and with higher risk of progression to stage 5 chronic kidney disease.

scholarly journals Pathophysiology and Pharmacological Treatment of Insulin Resistance*

2000 ◽  
Vol 21 (6) ◽  
pp. 585-618 ◽  
Author(s):  
Stephan Matthaei ◽  
Michael Stumvoll ◽  
Monika Kellerer ◽  
Hans-Ulrich Häring
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Progressive Disease ◽  
Glucose Production ◽  
Endogenous Glucose Production ◽  
Pharmacological Agents ◽  
Cell Dysfunction ◽  
Glucosidase Inhibitors ◽  
Type 2 Diabetic

Abstract Diabetes mellitus type 2 is a world-wide growing health problem affecting more than 150 million people at the beginning of the new millennium. It is believed that this number will double in the next 25 yr. The pathophysiological hallmarks of type 2 diabetes mellitus consist of insulin resistance, pancreatic β-cell dysfunction, and increased endogenous glucose production. To reduce the marked increase of cardiovascular mortality of type 2 diabetic subjects, optimal treatment aims at normalization of body weight, glycemia, blood pressure, and lipidemia. This review focuses on the pathophysiology and molecular pathogenesis of insulin resistance and on the capability of antihyperglycemic pharmacological agents to treat insulin resistance, i.e., α-glucosidase inhibitors, biguanides, thiazolidinediones, sulfonylureas, and insulin. Finally, a rational treatment approach is proposed based on the dynamic pathophysiological abnormalities of this highly heterogeneous and progressive disease.

scholarly journals Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity

2010 ◽  
Vol 13 (3) ◽  
pp. 62-65 ◽  
Author(s):  
Alexander Sergeevich Ametov ◽  
Elena Nikolaevna Pakus
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Lipid Metabolism ◽  
Beta Cells ◽  
Functional Activity ◽  
Pancreatic Beta Cells ◽  
Peripheral Insulin Resistance ◽  
Carbohydrate And Lipid Metabolism ◽  
Patients With Diabetes

Aim. To elucidate therapeutic effect of metformin-sitaglitin combination on the dynamics of indices of insulin resistance and functional activity of pancreaticbeta-cells, lipid metabolism and body weight in patients with type 2 diabetes mellitus (DM2) and obesity. Materials and methods. The study included 32 patients treated by a combination of metformin (500-2550 mg/day) and sitagliptin (100 mg) for18 weeks. Standard parameters of carbohydrate and lipid metabolism, body mass index (BMI), blood adiponectin and leptin levels were measured, indices of insulin resistance and functional activity of pancreatic beta-cells were calculated. Results. Therapy with metformin-sitagliptin combination ensured compensation of fasting and postprandial hyperglycemia, reduced HbA1c level, increasedfunctional activity of beta-cells, decreased peripheral insulin resistance and BMI, had beneficial effect on lipid metabolism and hormonalactivity of adipose tissue. Conclusion. Metformin-sitagliptin combination can be recommended as a clinically efficacious modality for the treatment of patients with diabetesmellitus and obesity.

Sign in / Sign up

Export Citation Format

Share Document